| Topical methimazole as a new treatment for postinflammatory hyperpigmentation: report of the first case. | |
| | |
MedLine Citation:
|
PMID: 16286748 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We have previously shown that the peroxidase inhibitor methimazole (1-methyl-2-mercapto imidazole; MMI) is a noncytotoxic inhibitor of melanin production in cultured B16 melanocytes. It was further demonstrated that the topical application of 5% MMI on brown guinea pig skin for 6 weeks causes a significant reduction in the amount of epidermal melanin, resulting in visually recognizable cutaneous depigmentation. Herein, we report a 27-year-old male with postinflammatory hyperpigmentation (due to acid burn), successfully treated with topical MMI as a new skin depigmenting agent. Topical 5% MMI caused a moderate to marked improvement of the hyperpigmented lesions within 6 weeks of once-daily application. Topical MMI was well tolerated by the patient and did not affect the level of serum thyroid hormones (free thyroxin, free triiodothyronine and the thyroid-stimulating hormone). Unlike most known depigmenting agents, such as hydroquinone and kojic acid, MMI is a noncytotoxic, nonmutagenic compound, and it is possible that MMI could serve as a novel agent for the treatment of hyperpigmentary disorders in human. |
| | |
Authors:
|
Behrooz Kasraee; Farhad Handjani; Amin Parhizgar; Gholamhosein R Omrani; Mohammad Reza Fallahi; Mitra Amini; Mohammad Nikbakhsh; Christian Tran; Ambros Hügin; Olivier Sorg; Jean-Hilaire Saurat |
Related Documents
:
|
9589778 - The role of growth hormone in substrate utilization. 2956108 - Anp--a cardiac hormone and a putative central neurotransmitter. 17478558 - Differential 3,5,3'-triiodothyronine-mediated regulation of uncoupling protein 3 transc... 14532698 - Substances derived from 4-ethyl octanoic acid account for primer pheromone activity for... 11312828 - Comparison of methylation procedures for conjugated linoleic acid and artifact formatio... 12153228 - A novel method for the construction of (z,e)- or (z,z)-conjugated alkadienyl carboxylates. |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Dermatology (Basel, Switzerland) Volume: 211 ISSN: 1018-8665 ISO Abbreviation: Dermatology (Basel) Publication Date: 2005 |
Date Detail:
|
Created Date: 2005-11-15 Completed Date: 2006-01-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203244 Medline TA: Dermatology Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 360-2 Citation Subset: IM |
Copyright Information:
|
Copyright 2005 S. Karger AG, Basel. |
Affiliation:
|
Jahrom School of Medical Sciences, Jahrom, Iran. kasraeeb@sums.ac.ir |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Cutaneous Adult Burns, Chemical / complications Dermatologic Agents / administration & dosage, therapeutic use* Facial Dermatoses / drug therapy* Humans Hyperpigmentation / drug therapy* Male Melanins / antagonists & inhibitors* Methimazole / administration & dosage, therapeutic use* Occupational Diseases / complications Peroxidase / antagonists & inhibitors Thyrotropin / blood Thyroxine / blood Triiodothyronine / blood |
| Chemical | |
Reg. No./Substance:
|
0/Dermatologic Agents; 0/Melanins; 60-56-0/Methimazole; 6893-02-3/Triiodothyronine; 7488-70-2/Thyroxine; 9002-71-5/Thyrotropin; EC 1.11.1.7/Peroxidase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A case of amicrobial pustulosis of the folds associated with neutrophilic gastrointestinal involveme...
Next Document: Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid...